Navigation Links
Contract Research Organization, WCCT Global, Welcomes Gary Urban as Executive Director, Corporate Compliance and Quality
Date:2/18/2013

Costa Mesa, California (PRWEB) February 18, 2013

WCCT Global, a contract research organization (CRO) supporting Phase I - IV biopharmaceutical and device development headquartered in Southern California, today welcomes Gary Urban as Executive Director, Corporate Compliance and Quality. As a Contract Research Organization professional for the past 16 years, Gary has held executive-level positions with global responsibility for Quality Management Systems, Clinical and Corporate Operations, and Information Technology. Gary earned a Bachelor of Science in Business Administration with a concentration in international business from Colorado Technical University. Gary is also certified in Good Clinical Practice and Lean Six Sigma Black Belt. When asked how Gary felt to be joining WCCT Global, he replied, “I am extremely excited to have joined this dynamic and growing organization, and look forward to leveraging my background in organizational optimization, leading companies successfully through growth and change, while ensuring the highest levels of quality, efficiency, and client and associate satisfaction.”
This is another great addition to WCCT Global because the service offering that WCCT Global is providing continues to grow which is why WCCT Global is contacted by sponsors all over the world to perform clinical studies in many different therapeutic areas. WCCT Global’s Chief Operating Officer Jon Rojas says, “Gary’s experience in I.T. and quality assurance allows WCCT Global to bring new technology, ensuring quality within our organization which in turn expands the breadth of services that we can offer to our clients.”
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
If you would like to request information about how WCCT Global can assist your organization with a clinical study, please CLICK HERE.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10437942.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PBM Experts to Discuss Non-Rate Contracting Terms in Feb. 25 Atlantic Information Services Webinar
2. MMS Group Explores New Opportunities for Placing Healthcare Contractors
3. EMR Staffing Partners Preparing for 25% Increase in Contract Staffing Business
4. Securityhunter, Inc. Selected as a Top 25 Baltimore Defense Contractor for the Baltimore Business Journal's 2013 Book of Lists
5. PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
6. NHS consultant contract fails to increase productivity
7. Care2Learn/Upstairs Solutions and Jarlette Health Services Sign Multi-Year Contract for Online Training and Record-Keeping
8. NIH awards Georgia malaria research consortium up to $19.4 million contract
9. Federal government renews contract for collecting and maintaining national stem cell transplantation database
10. BMC awarded contract to study validity of primary care drug screening tools
11. Collagenase for Dupuytrens contracture: Added benefit not proven
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... More than ... Hep B United Philadelphia, and the Prevent Cancer Foundation held an event on National ... epidemic in the city of viral hepatitis, the leading cause of liver cancer. , ...
(Date:5/31/2016)... ... 2016 , ... St. Joseph Medical Center (SJMC) announced that ... enables physicians at SJMC’s two hospital campuses, downtown and in the Heights, to ... exchange. SJMC’s membership in the health information exchange underscores the hospital’s commitment to ...
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop first demonstrated its ... something that contractors should have at their disposal on a daily basis. , ... Director of Contractor Programs. , As a result, Metloop and CertainTeed entered ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience ... enables unprecedented portability and convenience. , The Cube is exceptionally small—it takes up ... the Cube fits easily into any space, whether in a hospital, doctor’s office, ...
(Date:5/31/2016)... ... ... Like jewels in a crown, the multiple awards presented to Fayez Spa confirm ... day spa and one of Canada’s few accredited 5 Star Spas! , The ... spa services with hair and beauty services and has resulted in creating ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland , ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... agreement with Therawis Diagnostics GmbH to develop and commercialize predictive ... and market PITX2 as a marker to predict effectiveness of ... patients. "We are pleased to partner with Therawis, ...
Breaking Medicine Technology: